alexa Leandro Bueno Bergantin | Federal University of São Pa
ISSN: 2572-9462

Journal of Thrombosis and Circulation: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Leandro Bueno Bergantin

Leandro Bueno Bergantin Leandro Bueno Bergantin
Federal de University São Paulo
Brazil
Biography

Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): degree in biomedicine (2008), MSc (2010) and PhD (2014). His research involves cell signaling mediated by Ca2+ and cAMP, skeletal and smooth muscles, peripheral and central nervous systems. His research work solved the enigma of the paradoxical effects produced by Ltype Ca2+ channel blockers (TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/ TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. Despite this sympathetic hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and molecular mechanisms involved in this apparent sympathomimetic effect of the L-type CCB remained unclear for decades. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by L-type CCB is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of the Ca2+/cAMP interaction produced by combination of the L-type CCB used in the antihypertensive therapy, and cAMP accumulating compounds used in the antidepressive therapy, could represent a potential cardiovascular risk for hypertensive patients due to increase in sympathetic activity. In contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati-Neto et al., 2015 Pharm Res Perspect). Dr. Bergantin has published several articles in international journals, book chapters, and an international book. He is member of 20 editorial boards of international journals. Dr. Bergantin has been frequently invited to be honorable guest (speaker) in international conferences (e.g.: more than 30 invitations in 2016).

Research Interest

Pharmacology, Biochemistry, Genetics, Molecular Biology, Antihypertensive therapy, Biomedicine, Neurodegenerative diseases

Certificate
Certificate

Publications

Sudden Unexpected Death in Parkinson’s Disease and the Pharmacological Modulation of the Ca2+/cAMP Signaling Interaction: A Shot of Good News
Afonso Caricati-Neto1, Fúlvio Alexandre Scorza2 ,Carla Alessandra Scorza2, Roberta Monterazzo Cysneiros3, Francisco Sandro Menezes- Rodrigues1, and Leandro Bueno Bergantin1*
Short Communication: Brain Disord Ther 2017, 6:231
DOI: 10.4172/2168-975X.1000231
 
Insights for the Inhibition of Cancer Progression: Revisiting Ca2+ and Camp Signalling Pathways
Editorial: Adv Cancer Prev 2: e103
DOI: 10.4172/2472-0429.1000e103
 
A 4-Decade Enigma, Two Researchers and a Wonderful History
Editorial: Fam Med Med Sci Res 2017, 6:e109
DOI: 10.4172/2327-4972.1000e109
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords